skip to Main Content

Dr. Ocean on the Development of Nanoliposomal Irinotecan in Metastatic Pancreatic Cancer

Dr. Ocean on the Development of Nanoliposomal Irinotecan in Metastatic Pancreatic Cancer
Allyson Ocean, ​MD, an associate attending physician, NewYork-Presbyterian Hospital, and associate professor of clinical medicine at Weill Cornell Medicine, discusses the need for additional second-line therapies in metastatic pancreatic cancer.

FOLFIRINOX and the combination of gemcitabine plus nab-paclitaxel (Abraxane) have demonstrated survival advantages in the first-line setting for patients with metastatic pancreatic cancer, says Ocean. However, ​these patients often progress ​and require second-line therapy. Read more . . . 


Back To Top